Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
PharmaCyte Biotech Inc banner

PharmaCyte Biotech Inc
NASDAQ:PMCB

Watchlist Manager
PharmaCyte Biotech Inc Logo
PharmaCyte Biotech Inc
NASDAQ:PMCB
Watchlist
Price: 0.7 USD -1.02% Market Closed
Market Cap: $4.8m
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

Assets
+
3Y
-32%
5Y
+526%
10Y
+602%
Liabilities
+
3Y
+1 381%
5Y
+2 821%
10Y
+1 698%
Equity
+
3Y
-55%
5Y
+342%
10Y
+430%

Balance Sheet Decomposition
PharmaCyte Biotech Inc

Balance Sheet
PharmaCyte Biotech Inc

Rotate your device to view
Balance Sheet
Currency: USD
Apr-2002 Apr-2003 Apr-2004 Apr-2005 Apr-2006 Apr-2007 Apr-2008 Apr-2009 Apr-2010 Apr-2011 Apr-2012 Apr-2013 Apr-2014 Apr-2015 Apr-2016 Apr-2017 Apr-2018 Apr-2019 Apr-2020 Apr-2021 Apr-2022 Apr-2023 Apr-2024 Apr-2025
Assets
Cash & Cash Equivalents
0
0
0
0
1
1
2
1
0
0
0
0
4
3
2
3
1
1
1
2
85
68
50
15
Cash
0
0
0
0
1
1
2
1
0
0
0
0
4
3
2
3
1
1
1
2
85
68
50
15
Short-Term Investments
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
Total Receivables
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
Accounts Receivables
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Receivables
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Inventory
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Current Assets
0
0
0
0
2
2
1
0
0
0
1
2
1
1
0
0
0
0
0
0
0
0
0
0
Total Current Assets
0
0
0
0
3
3
4
1
0
0
1
2
4
4
2
4
1
1
1
2
85
68
50
22
PP&E Net
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
PP&E Gross
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Accumulated Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Intangible Assets
0
0
0
0
0
1
1
0
0
0
0
0
4
4
4
4
4
4
4
4
4
4
2
2
Goodwill
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Note Receivable
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
Long-Term Investments
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
2
2
0
28
Other Long-Term Assets
0
0
0
0
2
0
3
0
1
1
1
1
0
0
0
0
0
0
0
0
0
0
5
3
Other Assets
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Assets
0
N/A
0
N/A
0
N/A
0
+89%
5
+1 412%
4
-14%
8
+73%
6
-21%
1
-80%
1
+3%
2
+69%
3
+38%
9
+224%
9
0%
7
-23%
9
+21%
6
-26%
6
-10%
6
+7%
7
+20%
91
+1 125%
73
-19%
60
-18%
55
-8%
Liabilities
Accounts Payable
0
0
0
0
0
0
0
0
1
1
1
1
0
1
0
0
0
0
0
0
0
0
0
0
Accrued Liabilities
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
0
1
2
Short-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
1
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Current Liabilities
0
0
0
0
0
0
0
0
0
0
0
3
0
1
0
0
0
0
0
0
0
0
6
0
Total Current Liabilities
0
0
0
0
0
0
0
1
3
3
4
4
0
2
1
1
1
1
1
1
1
1
7
3
Long-Term Debt
0
0
0
1
1
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Liabilities
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
0
Total Liabilities
0
N/A
0
N/A
0
N/A
2
+394%
1
-56%
0
-83%
0
+50%
3
+1 522%
3
+8%
3
+8%
4
+12%
4
+0%
0
-90%
2
+311%
1
-58%
1
-9%
1
+10%
1
+16%
1
+46%
1
-33%
1
-3%
1
-16%
20
+3 356%
3
-84%
Equity
Common Stock
0
0
0
0
0
0
0
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
12
0
Retained Earnings
1
1
2
7
16
20
23
31
37
38
40
41
69
79
85
89
96
100
104
107
112
116
116
85
Additional Paid In Capital
1
1
2
5
20
24
31
32
34
34
38
40
76
86
91
97
102
105
109
114
202
202
185
181
Unrealized Security Profit/Loss
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Treasury Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
42
45
Other Equity
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
Total Equity
0
N/A
0
N/A
0
N/A
1
-767%
4
N/A
4
-3%
7
+73%
3
-58%
2
N/A
2
-10%
2
+21%
1
+46%
9
N/A
8
-13%
7
-16%
8
+24%
6
-29%
5
-13%
5
+1%
7
+31%
90
+1 246%
73
-19%
40
-46%
52
+31%
Total Liabilities & Equity
0
N/A
0
N/A
0
N/A
0
+89%
5
+1 412%
4
-14%
8
+73%
6
-21%
1
-80%
1
+3%
2
+69%
3
+38%
9
+224%
9
0%
7
-23%
9
+21%
6
-26%
6
-10%
6
+7%
7
+20%
91
+1 125%
73
-19%
60
-18%
55
-8%
Shares Outstanding
Common Shares Outstanding
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
2
21
17
8
7
Preferred Shares Outstanding
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

See Also

Summary
PMCB intrinsic value, competitors valuation, and company profile.
DCF Valuation
PMCB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PMCB stock valuation using valuation multiples.
Wall Street Estimates
PMCB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PMCB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 316,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.